DoW Duchenne Muscular Dystrophy Clinical/Translational Award
This grant funds advanced research to accelerate clinical applications for Duchenne muscular dystrophy, offering two funding levels and encouraging collaborative projects and therapies effective across all ages.
Funder: Dept. of the Army -- USAMRAA
Due Dates: September 4, 2026: Pre-Application (Letter of Intent) | September 18, 2026: Full Application | September 25, 2026: Application Verification
Funding Amounts: ~$8.46M total; Funding Level 1: up to $910,000 (single PI, 3 yrs) or $1M (PPIO); Funding Level 2: up to $1.75M (single PI, 4 yrs) or $1.9M (PPIO)
Summary: Supports advanced translational research to accelerate promising Duchenne muscular dystrophy (DMD) research toward clinical applications.
Description
This opportunity from the Dept. of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research with the goal of accelerating promising ideas in Duchenne muscular dystrophy (DMD) toward clinical applications. Projects must address at least one of the FY26 CTRA Focus Areas, with a strong emphasis on therapies with efficacy across the lifespan. Both preclinical and clinical research are eligible, including pilot clinical trials and clinical trial readiness studies. The program encourages collaborative projects, including a Partnering PI Option (PPIO) for early-career and established interdisciplinary investigators.
